Disease & Vaccine Information

Please select disease or vaccine
Ask 8 Information Kiosk

Explore FREE downloadable educational materials.

Connect with us!

Report Your Vaccine Experiences

Read and report vaccine reactions, harassment and failures. 

Who is at highest risk for complications from Meningococcal Vaccine?

Updated February 04, 2024


toddler walking with parent
 

 

Contraindications to receiving Menveo meningococcal (Groups A, C, Y, and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine documented in Novartis Vaccines and Diagnostics (GlaxoSmithKline) package insert include: 

  • Individuals who experienced a severe allergic reaction after a previous dose of Menveo, any component of the vaccine, or any other CRM197, diphtheria toxoid, or meningococcal-containing vaccine.

The Menveo vaccine package insert also warns that persons with a previous medical history of Guillain-Barre Syndrome (GBS) may be at an increased risk of the disease following administration with the vaccine. The decision to vaccinate should be made only after careful consideration of the potential risks and possible benefits to vaccination.

Infants born prematurely are considered to be at a greater risk for apnea following intramuscular vaccination. The Menveo meningococcal vaccine package insert warns that the decision to vaccinate an infant born prematurely should take into consideration both the potential risks and possible benefits of vaccination.

There are no well-controlled or adequate studies on the use of Menveo vaccine in pregnant women and no available data on the impact of Menveo vaccine on breastfeeding infants or on human milk excretion and production.

Menveo vaccine is approved for use in persons 2 months through 55 years of age. Menveo vaccine is not approved for use in infants younger than two months of age or in adults older than 55 years of age.

Contraindications to receiving MedQuadfi meningococcal (Groups A, C, Y, and W-135) conjugate vaccine documented in Sanofi Pasteur package insert include:  

  • Individuals who experienced a severe allergic reaction after a previous dose of MenQuadfi, any component of the vaccine, or tetanus toxoid.

The MenQuadfi vaccine package insert also warns that persons with a previous medical history of Guillain-Barre Syndrome (GBS) may be at an increased risk of the disease following administration with the vaccine. The decision to vaccinate should be made only after careful consideration of the potential risks and possible benefits to vaccination.

There are no well-controlled or adequate studies on the use of MenQuadfi vaccine in pregnant women and no available data on the impact of MenQuadfi vaccine on breastfeeding infants or on human milk excretion and production.

MenQuadfi vaccine is approved for use in persons two years of age and older. MenQuadfi vaccine is not approved for use in children younger than two years of age.

Contraindications to receiving BEXSERO meningococcal group B vaccine documented in Novartis Vaccines and Diagnostics (GlaxoSmithKline) package insert include: 

  • Individuals who experienced hypersensitivity or a severe allergic reaction after a previous dose of BEXSERO or to any ingredient found in the vaccine.

Persons with a latex sensitivity may be at greater risk for an allergic reaction if they receive a dose of BEXSERO from prefilled syringes as the tip caps of prefilled syringes contain natural rubber latex.

There are no well-controlled or adequate studies on the use of BEXSERO vaccine in pregnant women and no available data on the impact of BEXSERO vaccine on breastfeeding infants or on human milk excretion and production.

BEXSERO vaccine is approved for use in persons 10 through 25 years of age. BEXSERO vaccine is not approved for use in children younger than aged 10 or in adults older than 25 years.

Contraindications to receiving TRUMENBA meningococcal group B vaccine documented in Wyeth Pharmaceutical (Pfizer) package insert include a severe allergic reaction after a previous dose of TRUMENBA. 

There are no well-controlled or adequate studies on the use of TRUMENBA in pregnant women and no available data on the impact of TRUMENBA vaccine on breastfeeding infants or on human milk excretion and production. 

TRUMENBA vaccine is approved for use in persons 10 through 25 years of age. TRUMENBA vaccine is not approved for use in children younger than 10 years or in adults older than 25 years. The safety and effectiveness of TRUMENBA has not been evaluated in children under the age of 10 or in adults over the age of 65. 

Contraindications to receiving PENBRAYA meningococcal vaccine include a history of severe allergic reaction to any of the ingredients found within the vaccine. 

The PENBRAYA vaccine package insert also warns that persons with a previous medical history of Guillain-Barre Syndrome (GBS) may be at an increased risk of the disease following administration with the vaccine. The decision to vaccinate should be made only after careful consideration of the potential risks and possible benefits to vaccination. 

There are no well-controlled or adequate studies on the use of PENBRAYA vaccine in pregnant women and no available data on the impact of PENBRAYA vaccine on breastfeeding infants or on human milk excretion and production. 

PENBRAYA vaccine is FDA approved for use in individuals 10 through 25 years of age. PENBRAYA vaccine is not approved for use in children younger than 10 years of age or adults older than 25 years. 

NVIC “Quick Facts” is not a substitute for becoming fully informed about Meningococcal disease, meningitis and the Meningococcal vaccine. NVIC recommends consumers read the more complete information following the "Quick Facts", as well as the vaccine manufacturer product information inserts, and speak with one or more trusted health care professionals before making a vaccination decision for yourself or your child.


Opens in new tab, window
Opens an external site
Opens an external site in new tab, window